The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s chronic obstructive pulmonary disease COPD treatment market report forecasts the chronic obstructive pulmonary disease COPD treatment market size to grow to $24.52 Billion by 2027, with a CAGR (compound annual growth rate) of more than 5%.

Learn More On The Chronic Obstructive Pulmonary Disease COPD Treatment Market Report 2023 – https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-treatment-global-market-report

Chronic Obstructive Pulmonary Disease COPD Treatment Market Size Forecast
The global chronic obstructive pulmonary disease COPD treatment market is expected to grow from $19.18 billion in 2022 to $20.08 billion in 2023 at a compound annual growth rate (CAGR) of 4.71%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global chronic obstructive pulmonary disease (COPD) treatment market size is expected to reach $24.52 billion in 2027 at a CAGR of 5.12%.

North America held the largest chronic obstructive pulmonary disease COPD treatment market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Chronic Obstructive Pulmonary Disease COPD Treatment Market Driver ­– Increase In The Prevalence Of Lung Disease
According to the Global Initiative for Chronic Obstructive Lung Disease (GOLD), a non-profit organisation located in the United States, lung cancer caused more than 2.2 million new cases and 1.80 million deaths globally in 2020, accounting for one in every four cancer fatalities. Furthermore, 3.2 million people die each year as a result of chronic obstructive pulmonary disease (COPD), which affects an estimated 200 million people. Furthermore, asthma will impact 262 million people worldwide in 2022. These figures are projected to climb in the coming years. As a result, the rising prevalence of lung disease is propelling the chronic obstructive pulmonary disease (COPD) treatment market forward.

Request for A Sample Of The Global Chronic Obstructive Pulmonary Disease COPD Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10054&type=smp

Key Chronic Obstructive Pulmonary Disease COPD Treatment Market Trend – Product Innovation
To maintain their market position, major businesses in the chronic obstructive pulmonary disease (COPD) therapy market are focusing on introducing innovative solutions. For example, GlaxoSmithKline plc (GSK), a UK-based pharmaceutical and biotechnology company, launched Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol) in April 2022, the first single-inhaler triple treatment (SITT) for chronic obstructive pulmonary disease (COPD) patients in India. Trelegy Ellipta is used as a maintenance medicine in adults 18 years of age and older to treat and prevent the signs and symptoms of chronic obstructive pulmonary disease (COPD). It functions similarly to natural corticosteroid hormones in that it suppresses immune system activity by binding to receptors (targets) on specific immune cell types. It also aids in the reduction of edoema in the lungs’ airways.

Chronic Obstructive Pulmonary Disease COPD Treatment Market Segment
1) By Drug Class: Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics, Other Drug Classes
2) By Type: Chronic Bronchitis, Emphysema
3) By End-User: Hospitals, Clinics, Homecare Settings

Chronic Obstructive Pulmonary Disease COPD Treatment Market Major Players and Strategies
Major players in the chronic obstructive pulmonary disease Almirall S.A., AstraZeneca PLC, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GSK PLC., Novartis AG, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Abbott Laboratories, Chiesi Farmaceutici S.p.A, Mylan N.V., Orion Corporation, Sunovion Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Circassia Group PLC, Kyowa Kirin Co. Ltd., Circassia Group PLC, and Sanofi S.A.

PAOG, a biopharmaceutical technology business based in the United States, paid $200 billion for Resprx in July 2020. PAOG now has the ability to boost its long-term medicinal cannabis goal by entering the cannabis biopharmaceutical sector as a result of this acquisition. Resprx is a biopharmaceutical technology business established in the United States that offers cannabis-based COPD treatment.

The Chronic Obstructive Pulmonary Disease COPD Treatment Global Market Report 2023 covers regional data on chronic obstructive pulmonary disease COPD treatment market size, chronic obstructive pulmonary disease COPD treatment market trends and drivers, opportunities, strategies, and chronic obstructive pulmonary disease COPD treatment market competitor analysis. The countries covered in the chronic obstructive pulmonary disease COPD treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Chronic obstructive pulmonary disease (COPD) treatment refers to medical care provided to a patient to help manage symptoms, slow progression, and enhance overall quality of life. COPD is a progressive respiratory disease marked by airflow restriction, persistent inflammation, and lung tissue destruction.

View More Reports Related To The Chronic Obstructive Pulmonary Disease COPD Treatment Market –
Pulmonary Arterial Hypertension Global Market Report 2023
Chronic Disease Management Global Market Report 2023
Chronic Lower Back Pain Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: